BOSTON & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier in Europe, the Middle East and South America, announces today that the board of directors has received the resignation of GI Dynamics non-executive directors Anne Keating and Graham Bradley.
Both Keating and Bradley joined the GI Dynamics board of directors in 2011.
“I very strongly believe in our mission to commercialize EndoBarrier, providing a solution to the unmet global need of sufferers of type 2 diabetes and obesity,” said Keating. “It has been an honor working with a board and team of executives who are so committed.”
“EndoBarrier has the potential to improve the health and wellbeing of millions of people around the world afflicted with type 2 diabetes and obesity,” said Bradley. “It has been my privilege to serve on the board and to contribute to the Company’s efforts over the past six years.”
“Ms. Keating provided the company with extensive business and governance experience,” said Dan Moore, chairman of the board. “Mr. Bradley’s extensive financial background provided the company with significant financial expertise. We are extremely thankful for the notable contributions and dedication they have provided the company throughout the past six years.”
About GI Dynamics
GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.